Targeting of nanoparticles to the cerebral vasculature after traumatic brain injury

Serena Omo-Lamai,Jia Nong,Krupa Savalia,Brian J. Kelley,Jichuan Wu,Sahily Esteves-Reyes,Liam S. Chase,Vladimir R. Muzykantov,Oscar A. Marcos-Contreras,Jean-Pierre Dollé,Douglas H. Smith,Jacob S. Brenner

DOI: https://doi.org/10.1371/journal.pone.0297451

IF: 3.7

2024-06-10

PLoS ONE

Abstract:Traumatic brain injury has faced numerous challenges in drug development, primarily due to the difficulty of effectively delivering drugs to the brain. However, there is a potential solution in targeted drug delivery methods involving antibody-drug conjugates or nanocarriers conjugated with targeting antibodies. Following a TBI, the blood-brain barrier (BBB) becomes permeable, which can last for years and allow the leakage of harmful plasma proteins. Consequently, an appealing approach for TBI treatment involves using drug delivery systems that utilize targeting antibodies and nanocarriers to help restore BBB integrity. In our investigation of this strategy, we examined the efficacy of free antibodies and nanocarriers targeting a specific endothelial surface marker called vascular cell adhesion molecule-1 (VCAM-1), which is known to be upregulated during inflammation. In a mouse model of TBI utilizing central fluid percussion injury, free VCAM-1 antibody did not demonstrate superior targeting when comparing sham vs. TBI brain. However, the administration of VCAM-1-targeted nanocarriers (liposomes) exhibited a 10-fold higher targeting specificity in TBI brain than in sham control. Flow cytometry and confocal microscopy analysis confirmed that VCAM-1 liposomes were primarily taken up by brain endothelial cells post-TBI. Consequently, VCAM-1 liposomes represent a promising platform for the targeted delivery of therapeutics to the brain following traumatic brain injury.

multidisciplinary sciences